SG Americas Securities LLC Boosts Stock Holdings in Boston Scientific Co. (NYSE:BSX)

SG Americas Securities LLC lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 620.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 228,695 shares of the medical equipment provider’s stock after buying an additional 196,961 shares during the period. SG Americas Securities LLC’s holdings in Boston Scientific were worth $20,427,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Daymark Wealth Partners LLC grew its holdings in shares of Boston Scientific by 18.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 3,981 shares of the medical equipment provider’s stock valued at $356,000 after purchasing an additional 627 shares during the period. Investment Advisory Group LLC acquired a new position in Boston Scientific in the fourth quarter valued at approximately $205,000. Global Trust Asset Management LLC grew its position in Boston Scientific by 64.5% in the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 171 shares during the period. Dakota Wealth Management increased its stake in Boston Scientific by 17.7% during the fourth quarter. Dakota Wealth Management now owns 68,019 shares of the medical equipment provider’s stock worth $6,075,000 after acquiring an additional 10,224 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Boston Scientific by 2.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 388,795 shares of the medical equipment provider’s stock valued at $34,727,000 after purchasing an additional 10,969 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.6 %

Boston Scientific stock opened at $100.29 on Thursday. The stock’s fifty day moving average is $91.45 and its two-hundred day moving average is $84.93. The stock has a market cap of $147.81 billion, a PE ratio of 82.88, a P/E/G ratio of 2.59 and a beta of 0.80. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $101.65. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the company earned $0.50 EPS. On average, sell-side analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BSX shares. Stifel Nicolaus raised their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Citigroup upped their price objective on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, TD Cowen upped their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.26.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,989 shares of company stock worth $2,702,261 over the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.